消化

订阅

MedSci主页 / 所有栏目 / 消化

FDA警告：与AbbVie、默克、吉利德的丙型肝炎药物有关的罕见严重肝损伤病例

2019-08-29 Allan MedSci原创

丙型肝炎药物FDA警告严重肝损伤
关注

美国食品和药物管理局（FDA）本周三（2019年8月28日）发布了药物安全通报，称了63例肝功能失代偿患者在使用AbbVie的Mavyret（glecaprevir / pibrentasvir）、默克的Zepatier（elbasvir / grazoprevir）和吉利德科学的Vosevi（sofosbuvir / velpatasvir / voxilaprevir）治疗丙型肝炎后，出现肝功

美国食品和药品监督管理局（FDA）本周三（2019年8月28日）发布了药物安全通报，称了63例肝功能失代偿患者在使用AbbVie的Mavyret（glecaprevir / pibrentasvir）、默克的Zepatier（elbasvir / grazoprevir）和吉利德科学的Vosevi（sofosbuvir / velpatasvir / voxilaprevir）治疗丙型肝炎后，出现肝功能衰竭和死亡。美国FDA称：“所有这些药物都含有丙型肝炎病毒蛋白酶抑制剂，这些蛋白酶抑制剂或许并不适用于中度至重度肝功能损害的患者”。


原始出处：

http://www.firstwordpharma.com/node/1662509#axzz5xwhWnSXE

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1273920, encodeId=a7de12e3920ae, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274673, encodeId=3f3112e467337, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338811, encodeId=35ee133881136, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397815, encodeId=3086139e81586, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467482, encodeId=8471146e4827d, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479595, encodeId=88f214e95953a, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
    2019-08-31 makuansheng

    #默克#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1273920, encodeId=a7de12e3920ae, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274673, encodeId=3f3112e467337, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338811, encodeId=35ee133881136, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397815, encodeId=3086139e81586, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467482, encodeId=8471146e4827d, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479595, encodeId=88f214e95953a, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
    2019-08-31 zjubiostat

    #丙型肝炎#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1273920, encodeId=a7de12e3920ae, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274673, encodeId=3f3112e467337, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338811, encodeId=35ee133881136, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397815, encodeId=3086139e81586, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467482, encodeId=8471146e4827d, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479595, encodeId=88f214e95953a, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
    2019-08-31 12498bd5m16暂无昵称

    #肝损伤#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1273920, encodeId=a7de12e3920ae, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274673, encodeId=3f3112e467337, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338811, encodeId=35ee133881136, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397815, encodeId=3086139e81586, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467482, encodeId=8471146e4827d, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479595, encodeId=88f214e95953a, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
    2019-08-31 仁者大医

    #损伤#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1273920, encodeId=a7de12e3920ae, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274673, encodeId=3f3112e467337, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338811, encodeId=35ee133881136, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397815, encodeId=3086139e81586, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467482, encodeId=8471146e4827d, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479595, encodeId=88f214e95953a, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
    2019-08-31 syscxl

    #罕见#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1273920, encodeId=a7de12e3920ae, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103353, encryptionId=4909103353c5, topicName=默克)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274673, encodeId=3f3112e467337, content=<a href='/topic/show?id=30872089e03' target=_blank style='color:#2F92EE;'>#丙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20897, encryptionId=30872089e03, topicName=丙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f503121, createdName=zjubiostat, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338811, encodeId=35ee133881136, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397815, encodeId=3086139e81586, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467482, encodeId=8471146e4827d, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479595, encodeId=88f214e95953a, content=<a href='/topic/show?id=135e1e1794' target=_blank style='color:#2F92EE;'>#Abbvie#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1717, encryptionId=135e1e1794, topicName=Abbvie)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34847549422, createdName=12498768m15(暂无昵称), createdTime=Sat Aug 31 01:09:00 CST 2019, time=2019-08-31, status=1, ipAttribution=)]
    2019-08-31 12498768m15(暂无昵称)

    #Abbvie#

    0